Evaluating the result of cytoreductive surgery after neoadjuvant chemotherapy in advanced epithelial ovarian cancer
Nội dung chính của bài viết
Tóm tắt
A retrospective study of 61 patients was conducted to evaluate the preliminary results of maximal cytoreductive surgery following neoadjuvant chemotherapy for FIGO stage IIIC-IV ovarian cancer from 2019 to 2023. The patients were diagnosed with FIGO staged IIIC (54.1%) and IV (45.9%), confirmed by preoperative histopathology. Elevated CA 125 level (> 1000 UI/ml) was found in 45 patients (73.8%). The rate of patients achieving optimal surgery was 80.4%. The mean surgery time was 134.1 ± 39.1 minutes, the average blood loss in 1 surgery was 171.2 ± 144.9mL. The drainage volume during the first 3 days was 115.4 ± 38.1mL. The patient started passing gas 3.9 ± 1.0 days after surgery, and started walking after 8.3 ± 2.0 days. The discharged day was 10.1 ± 2.1 days. After surgery, only 1 patient had intestinal obstruction, 2 patients had infection, 2 patients had bleeding, 1 patient had bladder dysfunction, and the remaining patients were stable postoperatively.
Chi tiết bài viết
Từ khóa
Ovarian cancer, maximal cytoreductive surgery, neoadjuvant chemotherapy
Tài liệu tham khảo
2. Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer. Nature Reviews Disease Primers. 2016;2(1):16061. doi:10.1038/nrdp.2016.61
3. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995;332(10):629-634. doi:10.1056/NEJM199503093321002
4. Bacry MC, Philippe AC, Riethmuller D, et al. Interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer - retrospective study comparing surgery after 3 cycles or more of chemotherapy. Journal of Gynecology Obstetrics and Human Reproduction. 2022;51(7):102409. doi:10.1016/j.jogoh.2022.102409
5. Medina-Franco H, Mejía-Fernández L. Neoadjuvant chemotherapy and interval debulking surgery for advanced ovarian cancer, an alternative with multiple advantages. Chinese Clinical Oncology. 2018;7(6):57-57. doi:10.21037/cco.2018.06.10
6. Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22-33. doi:10.1016/j.ejca.2016.01.017
7. Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680-1687. doi:10.1016/S1470-2045(18)30566-7
8. Gao Y, Li Y, Zhang C, et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2019;12:85. doi:10.1186/s13048-019-0562-9
9. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953. doi:10.1056/NEJMoa0908806
10. Pham Thi Dieu Ha, Nguyen Van Tuyen. The value of tumor marker HE4 and ROMA tests in diagnosis ovarian cancer. Journal of Medical Research. 2013;82(2):37-44.
11. Lee YJ, Chung YS, Lee JY, et al. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. J Gynecol Oncol. 2018;29(4):e63. doi:10.3802/jgo.2018.29.e63
12. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, et al. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;2016(1):CD006014. doi:10.1002/14651858.CD006014.pub7
13. Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114-125. doi:10.1016/j.ejca.2020.02.020
14. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-257. doi:10.1016/S0140-6736(14)62223-6